. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Cancer Lett. 2015 Jan 15;359(1):20–35. doi: 10.1016/j.canlet.2015.01.016

Table 2.

Selected clinical trials of synthetic small molecule inhibitor combinations in metastatic melanoma

Inhibitor combination	Target(s)	Phase of clinical trial	Treatment effect or trial status	Mutations selected in patient population	Reference or NCT trial number (if not completed)
Dabrafenib and trametinib compared to dabrafenib monotherapy	BRAF + MEK1/2	Phase II Phase III	No significant improvement in PFS In progress	BRAF^V600 BRAF^V600	89 NCT01584648
Dabrafenib and trametinib compared to verumafenib monotherapy	BRAF + MEK1/2	Phase III	In progress	BRAF^V600E BRAF^V600K	NCT01597908
Sorafenib with temsirolimus or Sorafenib with tipifarnib	BRAF + mTOR or BRAF + RAS	Phase II	No significant improvement in PFS	None selected	120
LGX818 plus MEK162 and LGX818 monotherapy to verumafenib monotherapy	BRAF + MEK1/2	Phase III	In progress	BRAF^V600	NCT01909453
Cobimetinib in combination with vermurafenib	BRAF + MEK1/2	Phase Ib	Anti-tumor activity	BRAF^V600	91
Cobimetinib in combination with vemurafenib vs vemurafenib alone	BRAF + MEK1/2	Phase III	In progress	brafV6⁰⁰	NCT01689519

OS – Overall survival, PFS – Progression free survival, RR – Response Rate